John Nakayama is an Oncology physician affiliated with Allegheny Health Network. OpenAlex indexes 63 publications with 3,101 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4815 Liberty Ave Ste 310
Pittsburgh, PA 152242156
Telephone
412-578-1116Provider last certified this registry record 24 Feb 2021.
Clinical trials
- Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202514 payments$23,731openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year202515 payments$18,649openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
79.3%Corticosteroid79.3%Dexamethasone100%Part D≥15 patientsNervous system
20.7%Phenothiazine20.7%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care Network
Journal of Molecular Diagnostics
2025 - Müllerian clear cell carcinoma arising from rectal endometriosis with pericolonic lymph node metastasis
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kalathil Sureshkumar, MD
Allegheny Health Network
Susan Manzi, MD
Allegheny Health Network
Blair Jobe, MD
Allegheny Health Network
Sushil Beriwal, MD
Allegheny Health Network
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”